Can a quick drug pulse make prostate cancer cells more vulnerable?
NCT ID NCT03507608
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study looked at whether giving a single, short course of the drug flutamide can create DNA breaks in prostate cancer cells. The 25 participants were already receiving standard hormone therapy and brachytherapy (internal radiation). The goal was to see if this approach could make cancer cells more sensitive to treatment, not to cure the disease. The study was completed and focused on measuring biological changes in the tumor.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
SKCCC at Johns Hopkins
Baltimore, Maryland, 21287, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new tracer light up hidden prostate cancer?
- Could deep breaths before surgery ward off Post-Op confusion?
- A second look: MRI screening may spot hidden prostate cancers
- Can precision protons spare the bowel in prostate cancer?
- AI coaches doctors on cancer risk talks
- Can an immune booster make hormone therapy work better against prostate cancer?